Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

PURPOSE: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its correlation with patient survival outcomes during anti–PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Xue, Hu, Jiani, Betof Warner, Allison, Quach, Henry T., Cann, Christopher G., Zhang, Michael Z., Si, Lu, Tang, Bixia, Cui, Chuanliang, Yang, Xiaoling, Wei, Xiaoting, Pallan, Lalit, Harvey, Catriona, Manos, Michael P., Ouyang, Olivia, Kim, Michelle S., Kasumova, Gyulnara, Cohen, Justine V., Lawrence, Donald P., Freedman, Christine, Fadden, Riley M., Rubin, Krista M., Sharova, Tatyana, Frederick, Dennie T., Flaherty, Keith T., Rahma, Osama E., Long, Georgina V., Menzies, Alexander M., Guo, Jun, Shoushtari, Alexander N., Johnson, Douglas B., Sullivan, Ryan J., Boland, Genevieve M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401488/
https://www.ncbi.nlm.nih.gov/pubmed/34376536
http://dx.doi.org/10.1158/1078-0432.CCR-21-1283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401488/
https://www.ncbi.nlm.nih.gov/pubmed/34376536
http://dx.doi.org/10.1158/1078-0432.CCR-21-1283

Ejemplares similares